NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 128)
Posted On: 02/09/2018 5:46:51 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Advancing Work on Novel Delivery for Cannabinoid Therapies
A partnership between health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Australia’s UniQuest Pty Limited aimed at furthering research and development of a soluble gel is working toward a novel means of delivering cannabinoids to the central nervous system directly from the nasal cavity in order to treat pain, inflammation, seizures and neurological disorders. The partnership is taking advantage of the growing legalization of medical marijuana throughout the world amid increasing evidence of cannabinoids’ benefits. An article discussing this reads: “The global nasal drug delivery technology market is projected to reach $64 billion by 2021, expanding at a compound annual growth rate of 6.5 percent, according to a report issued by MarketsandMarkets (http://nnw.fm/usd0S). While the report is segmented based on dosage form, therapeutic application, end user, system, container and region, it also states ‘intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
A partnership between health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and Australia’s UniQuest Pty Limited aimed at furthering research and development of a soluble gel is working toward a novel means of delivering cannabinoids to the central nervous system directly from the nasal cavity in order to treat pain, inflammation, seizures and neurological disorders. The partnership is taking advantage of the growing legalization of medical marijuana throughout the world amid increasing evidence of cannabinoids’ benefits. An article discussing this reads: “The global nasal drug delivery technology market is projected to reach $64 billion by 2021, expanding at a compound annual growth rate of 6.5 percent, according to a report issued by MarketsandMarkets (http://nnw.fm/usd0S). While the report is segmented based on dosage form, therapeutic application, end user, system, container and region, it also states ‘intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PreveCeutical Medical Inc. (PRVCF) Stock Research Links
Scroll down for more posts ▼